Better measurement of NASH liver scarring changes
Part of Digestive system clinical trials.
This study is for people with NASH and moderate-to-advanced liver scarring (fibrosis). Researchers want to see if they can better measure how the scarring changes over time using a liver biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had a liver biopsy showing NASH and stage 2, 3, or 4 fibrosis (a certain amount of liver scarring).
- You do not have other liver diseases like viral hepatitis, alcoholic liver disease, or autoimmune hepatitis.
- You are not pregnant.
- You do not have liver cancer, severe cirrhosis complications, or another cancer, and you have not had a liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
This study tests a better way to check for advanced liver scarring (cirrhosis) in people with fatty liver disease. It might help you avoid unnecessary procedures if you have metabolic liver disease and are at risk of serious liver problems.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.